| NFACX | NPFCX | NFACX / NPFCX | |
| Total Expense Ratio | 1.87 | 1.47 | 127% |
| Annual Report Gross Expense Ratio | 1.96 | 1.47 | 133% |
| Fund Existence | 16 years | 25 years | - |
| Gain YTD | 6.923 | 5.694 | 122% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 250 | 400% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 830M | 172B | 0% |
| Annual Yield % from dividends | 0.00 | 0.33 | - |
| Returns for 1 year | 4.11 | 7.23 | 57% |
| Returns for 3 years | 49.08 | 34.20 | 143% |
| Returns for 5 years | 0.38 | 9.29 | 4% |
| Returns for 10 years | -27.46 | 103.38 | -27% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBTIX | 50.96 | 1.28 | +2.58% |
| Fidelity Advisor Biotechnology I | |||
| IVFCX | 4.81 | 0.09 | +1.91% |
| Federated Hermes Intl Strat Val Div C | |||
| ECASX | 24.40 | 0.35 | +1.46% |
| Eaton Vance Atlanta Capital SMID-Cap C | |||
| JHACX | 10.22 | 0.01 | +0.10% |
| JHancock Multi-Asset Absolute Return C | |||
| EVCGX | 15.90 | -0.26 | -1.61% |
| Eaton Vance China Equity A | |||